MetaCap

Celularity Inc. Class A Company Profile

NASDAQ: CELUHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.463-0.0049 (-1.05%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Celularity at a glance

Celularity Inc. Class A (NASDAQ: CELU) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Florham Park, NJ. Celularity is led by Dr. Robert Joseph Hariri M.D., Ph.D. and employs about 115 people. The company's shares have traded publicly since 2019.

At a market capitalization of $15.2 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001752828, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Celularity do?

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.

Business description based on the company's public filings.

Company information

Legal name
Celularity Inc. Class A
Ticker
NASDAQ: CELU
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Robert Joseph Hariri M.D., Ph.D.
Employees
115
Headquarters
170 Park Avenue, Florham Park, NJ, United States
Phone
908 768 2170
IPO year
2019
Market cap
$15.18M
SEC CIK
0001752828
Latest annual report
10-K/A · Oct 20, 2026

Companies similar to Celularity

CELU peer companies
CompanyPrice% ChgMarket capCompare
CNTXContext Therapeutics Inc.0.16-5.10%$14.70Mvs CELU
NCELNewcelX Ltd.2.54-5.58%$14.67Mvs CELU
QNRXQuoin Pharmaceuticals Ltd. ADR3.28-2.35%$15.76Mvs CELU
PBMPsyence Biomedical Ltd.2.97+3.85%$15.80Mvs CELU
ATOSAtossa Therapeutics Inc.1.60-8.86%$15.92Mvs CELU
LPCNLipocine Inc.1.48-1.33%$16.39Mvs CELU
CTXRCitius Pharmaceuticals Inc.0.5085+2.27%$13.96Mvs CELU
SHPHShuttle Pharmaceuticals Holdings Inc.3.49-10.51%$16.63Mvs CELU

Related